We thank Dr. Dong et al. for their expedient and thorough appraisal. We agree with most of their comments.
We scan the top radiology sources so you don’t have to.
From AI breakthroughs to imaging trends, we serve up real-time radiology insights.
-
Response to Letter – referencing JCCT-D-25-426 ‘‘Integrating radiomics into coronary computed tomography angiography: Enhancing prognostic value after percutaneous coronary intervention’’ by Macit Kalçık et al.
We sincerely thank Dr. Macit Kalçık and colleagues for their thoughtful comments on our article. Their remarks aptly highlight the significance of integrating radiomics into coronary computed tomography angiography (CCTA) as a means to advance risk stratification in clinical practice.
-
High-risk plaques in proximal and distal segments relative to graft anastomoses and non-grafted segments
Coronary artery bypass grafting (CABG) is the preferred invasive treatment option for complex coronary artery disease (CAD), bypassing flow-limiting lesions and high-risk plaques (HRP), thereby reducing clinical events. It also provides graft collateralization, preventing cardiac events due to proximal plaque rupture or erosion, and vessel occlusion. This study evaluated the prevalence of HRPs in segments proximal and distal to graft anastomoses and in non-grafted segments, using coronary comput…
-
Incremental value of a CCTA-derived AI-based ischemia algorithm over standard CCTA interpretation of predicting myocardial ischemia in patients with suspected coronary artery disease
A novel artificial intelligence-guided quantitative computed tomography ischemia algorithm (AI-QCTischemia) comprises a machine-learned method using atherosclerosis and vascular morphology features from coronary computed tomography angiography (CCTA) images to predict myocardial ischemia. This study evaluates the diagnostic performance of AI-QCTischemia compared to standard CCTA interpretation in detecting myocardial ischemia.
-
Lifestyle May Preserve Bone Health in Seniors With Obesity
Diet and exercise can preserve bone quality in older adults with obesity, despite reductions in bone mineral density. Medscape Medical News
-
Clairity to Present AI Research in Breast Cancer Risk Prediction at RSNA 2025
tim.hodson
Tue, 10/07/2025 – 12:51
Oct. 7, 2025 – Clairity Inc., a leader in AI-based breast cancer risk prediction, will make five scientific presentations featuring its FDA-authorized image-only AI model at the Radiological Society of North America (RSNA) 2025 Annual Meeting, Nov. 30 to Dec. 4 in Chicago. The studies highlight Clairity’s approach to estimating 5-year breast cancer risk from a single screening mammogram and demonstrate the model’s clinical accuracy, calibration, a…
-
CT Study Shows No Significant Difference in Long-Term Outcomes Between Surveillance and Surgery for Ground-Glass Nodules
Researchers found comparable 10-year overall survival rates for people who had computed tomography (CT) surveillance (94.7 percent) and those who had surgery for ground-glass nodules (97.6 percent), according to a new prospective study involving over 680 participants.
-
Lobular breast cancer incidence rising
Invasive lobular breast cancer incidence has risen by between 2.5% and 4.4% among women of various ethnic and racial backgrounds…
-
AI System Surpasses Radiologists in Detecting Prostate Cancer on MRI, New Study Shows
by Christos Evangelou, MSc, PhD – Medical Writer and Editor In a recent study, an international consortium of researchers evaluated the ability of an artificial intelligence (AI) system to detect clinically significant prostate cancer using multiparametric magnetic resonance imaging (MRI). The study showed that an AI system was superior in discriminating clinically significant […]
Source -
Current Perspectives on Prostate Cancer and Emerging Theranostic Agents, Part 1
In a recent interview, Emmanuel S. Antonarakis, M.D. discussed contributing factors to the recent American Cancer Society report about rising prostate cancer incidence and offered insights about the potential role of the radioligand agent 177Lu-PSMA-I&T for patients with mCRPC.